Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Boston Scientific maintains buy rating, steady price target on the success of Farapulse

EditorNatashya Angelica
Published 21/05/2024, 01:10 am
BSX
-

On Monday, TD Cowen sustained its Buy rating on Boston Scientific (NYSE:BSX) with a steady stock price target of $77.00. The firm's endorsement follows the reported success of Boston Scientific's Farapulse, which has treated 70,000 patients worldwide. The technology's adoption in the U.S. has been particularly notable since its launch in February.

The analyst from TD Cowen highlighted the recent clinical and real-world results presented at the Heart Rhythm Society (HRS) meeting. These findings bolster the existing data on Farapulse, showcasing the system's safety, efficacy, and the reproducibility of its procedures. This positive data is expected to support Farapulse's sales momentum.

Despite new competitors entering the market, Farapulse is anticipated to continue its strong performance in the U.S. The system's growing adoption and the clinical results are seen as key drivers for Boston Scientific's ongoing success in the pulsed field ablation (PFA) sector.

Boston Scientific's Farapulse is part of a competitive landscape in the medical device industry, where innovation and proven results are critical for maintaining growth. The company's ability to meet these standards has been recognized by TD Cowen's consistent Buy rating and price target, indicating confidence in Boston Scientific's market position.

Investors and market watchers will likely keep a close eye on Boston Scientific's performance as it navigates the competitive environment with its Farapulse system. The continued endorsement by TD Cowen suggests a positive outlook for the company's stock.

InvestingPro Insights

As Boston Scientific (NYSE:BSX) continues to impress with its Farapulse technology, real-time data and insights from InvestingPro further illuminate the company's financial health and market position.

With a robust market capitalization of $110.7 billion and a revenue growth of 12.74% over the last twelve months as of Q1 2024, Boston Scientific is demonstrating its capacity to expand and innovate in the healthcare sector. The company's gross profit margin stands at a strong 69.0%, underscoring its ability to maintain profitability amidst competitive pressures.

InvestingPro Tips highlight that Boston Scientific is expected to see net income growth this year and that 19 analysts have revised their earnings upwards for the upcoming period. This consensus suggests a positive momentum that could be reflective of the company's strategic initiatives and the market's reception of its Farapulse technology.

Moreover, the stock is trading at a low P/E ratio relative to near-term earnings growth, which could indicate an attractive valuation for investors considering the company's growth prospects.

For those seeking further insights and analysis, InvestingPro offers additional tips on Boston Scientific, which can be accessed through https://www.investing.com/pro/BSX. Use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, unlocking a wealth of investment knowledge and tools. With InvestingPro, investors can stay ahead of the curve with real-time data and expert analysis.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.